LAF389

LAF389, a benaamide B analogue, is a methionine aminopeptidases (MetAps) inhibitor with an IC50 of 800 nM for MetAp2. LAF389 has both antiproliferative and antiangiogenetic properties and can inhibit tumor cells growth. LAF389 can be used for the research of cancer[1][2].

Product Specifications

CAS Number

[270902-51-7]

UNSPSC

12352005

Target

MetAP

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

CC(C)(C)/C=C/[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC)C(N[C@H]1CC[C@H](CNC1=O)OC(C2CCCCC2)=O)=O

Molecular Formula

C25H42N2O8

Molecular Weight

498.61

References & Citations

[1]Towbin H, et al. Proteomics-based target identification: bengamides as a new class of methionine aminopeptidase inhibitors. J Biol Chem. 2003 Dec 26;278 (52) :52964-71.|[2]Dumez H, et al. A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer. Anticancer Drugs. 2007 Feb;18 (2) :219-25.